By Lina carolina 
Breakthrough Discovery Targets Crucial Gene in Childhood Brain Cancer
Toronto, ON – In a significant stride toward combating one of the most prevalent and aggressive childhood brain cancers, researchers at The Hospital for Sick Children (SickKids) have pinpointed a critical gene, KCNB2, that plays a pivotal role in the survival and proliferation of medulloblastoma tumour cells. This groundbreaking discovery, published in the esteemed journal Developmental Cell, offers a promising new avenue for developing next-generation therapies that could revolutionize the treatment of this devastating disease.
Medulloblastoma, a malignant tumour originating in the cerebellum, accounts for approximately 20% of all pediatric brain tumours and remains a leading cause of cancer-related mortality in children. While advancements in surgery, radiation, and chemotherapy have improved survival rates over the decades, a significant challenge persists: the presence of highly resilient cells within the tumour, often referred to as tumour-propagating cells (TPCs). These TPCs are the architects of tumour growth and are notoriously resistant to conventional treatments, leading to a high incidence of tumour recurrence and relapse, even after initial successful treatment. The relentless nature of these TPCs underscores the urgent need for novel therapeutic strategies that can effectively target and eradicate them.
Unraveling the Mechanics of Tumour Persistence
The SickKids research team, led by Dr. Xi Huang, a Senior Scientist in the Developmental, Stem Cell & Cancer Biology program, and Dr. Michael Taylor, an Adjunct Scientist at SickKids and Professor at Baylor College of Medicine and Texas Children’s Cancer Center, embarked on an ambitious quest to identify the genetic underpinnings of medulloblastoma’s tenacious hold. Their investigation utilized a sophisticated genetically engineered preclinical model, meticulously designed to mimic the complexities of human medulloblastoma. This innovative approach allowed researchers to systematically screen for genes that are indispensable for tumour growth and survival.
The screening process, described by Dr. Taylor as akin to identifying "key blocks in a tower that are necessary to keep the tower standing," yielded a list of critical genes. Among these, a particular focus emerged on genes involved in potassium channels. These channels are fundamental cellular components that regulate the flow of potassium ions in and out of cells, a process crucial for maintaining cellular function and integrity.
The Role of Potassium Channels in Tumour Propagation
Further analysis by Dr. Jerry Fan, the study’s first author and a former Ph.D. student in Dr. Huang’s lab, revealed that one specific potassium channel, encoded by the KCNB2 gene, is disproportionately active in medulloblastoma TPCs. This finding was further corroborated by an analysis of the medulloblastoma transcriptome, which indicated that potassium channels are present at elevated levels in human tumours, exceeding expected physiological concentrations.
"Tumour-propagating cells are the main reason tumours grow and come back," explained Dr. Huang. "By targeting a specific potassium channel, we were able to reduce tumour growth without impacting surrounding healthy cells. This discovery opens the door to developing new therapies that could transform how we treat this common childhood brain cancer."
The research detailed a fascinating mechanism by which KCNB2 contributes to tumour growth. Potassium channels, including the one regulated by KCNB2, play a vital role in maintaining the osmotic balance within cells. Potassium ions help to regulate the movement of water across the cell membrane, preventing excessive swelling. In the context of medulloblastoma, the heightened activity of KCNB2 appears to enable TPCs to control their internal water balance, allowing them to maintain their integrity and continue to divide and propagate.
"Without KCNB2, the tumour cells began to lose their integrity, triggering a chain of events that eventually interrupts the tumour propagation process and stops tumour growth," Dr. Fan elaborated.
A Novel Mechanism of Cell Death
The research unveiled a compelling analogy to understand how blocking KCNB2 leads to tumour cell demise. Potassium is an essential ion that supports numerous human functions, including the regulation of fluid levels within cells. The scientists likened the cell’s internal environment to a water balloon. If a water balloon takes in too much water, it bursts. Similarly, when the KCNB2 channel is inhibited, medulloblastoma tumour cells experience an uncontrolled influx of water, causing them to swell and expand. This cellular distension leads to the disruption of vital internal structures, effectively halting the mechanisms that drive tumour growth and propagation. This targeted approach offers a distinct advantage over traditional therapies, as it specifically targets a vulnerability unique to the cancerous cells, potentially minimizing collateral damage to healthy tissues.
A Timeline of Discovery and Future Directions
The journey to this pivotal discovery was a meticulous process spanning several years, reflecting the complex nature of cancer research. While specific dates for the inception of this particular project were not provided, the research likely began with initial observations of gene expression patterns in medulloblastoma samples, followed by the development and refinement of preclinical models in the preceding years. The identification of candidate genes associated with tumour growth would have occurred through systematic screening. The subsequent focus on potassium channels and the detailed investigation of KCNB2‘s role would have followed, culminating in the publication of these findings in Developmental Cell.
The research team’s commitment to translating these findings into tangible clinical benefits is evident in their ongoing work. The SickKids Industry Partnerships & Commercialization (IP&C) office has been instrumental in facilitating the next phase of this research. Dr. Huang has collaborated with a specialized ion channel drug discovery company, a process that typically involves rigorous evaluation of vast libraries of potential therapeutic compounds. This evaluation encompassed over 30,000 small molecules, each screened for its ability to inhibit the function of the KCNB2 gene.
The current focus is on validating the efficacy of these identified molecules. The ranked candidates are undergoing further rigorous testing in preclinical models to assess their therapeutic potential in a more complex biological environment. This validation process is crucial to ensure that any potential drug is not only effective but also safe and well-tolerated.
"Identifying the molecule that can most effectively block KCNB2 is our next milestone to develop an effective targeted therapy for medulloblastoma," stated Dr. Huang. "I am grateful to have dedicated support from IP&C at SickKids to help ensure these findings will move beyond the lab, and towards real-world therapies for patients."
Broader Implications and Future Prospects
The implications of this research extend beyond the immediate development of new medulloblastoma treatments. The identification of a critical vulnerability in tumour-propagating cells through a targeted ion channel mechanism could pave the way for similar therapeutic strategies against other aggressive and treatment-resistant cancers that also harbor these resilient cell populations. The success of this approach hinges on the ability to selectively target specific ion channels that are dysregulated in cancer cells, thereby sparing healthy tissues.
The findings also highlight the increasing sophistication of genetic and molecular research in pediatric oncology. The ability to dissect the intricate genetic machinery of cancer cells and identify specific molecular targets represents a paradigm shift in cancer treatment, moving away from broad-spectrum therapies towards highly personalized and precise interventions.
The comprehensive list of funding sources for this study underscores the collaborative and multi-faceted nature of modern scientific endeavors. Grants from organizations such as the Sontag Foundation, Ontario Early Researcher Award program, Canadian Cancer Society, Cancer Research Society, Natural Sciences and Engineering Research Council (NSERC), American Brain Tumor Association, Ontario Institute for Cancer Research, Canadian Institutes of Health Research (CIHR), National Institutes of Health (NIH), b.r.a.i.n.child, Meagan’s HUG, and the Cancer Prevention and Research Institute of Texas (CPRIT) demonstrate a broad commitment to advancing research in pediatric brain cancer. Dr. Michael Taylor’s designation as a CPRIT Scholar in Cancer Research and his affiliation with the Texas Children’s Cancer and Hematology Center further emphasize the international collaboration and dedication to this critical area of research.
While the path from laboratory discovery to clinical application is often long and challenging, the identification of KCNB2 as a crucial target for medulloblastoma represents a significant beacon of hope for children and families affected by this formidable disease. The meticulous research conducted at SickKids is a testament to the power of scientific inquiry and the unwavering dedication of researchers striving to conquer childhood cancer. The continued collaboration between academic institutions, pharmaceutical companies, and funding bodies will be paramount in translating these promising findings into life-saving therapies for future generations.
